Navigation Links
Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
Date:2/28/2008

Robert G. Johnson, Jr. Resigns as President and Chief Executive Officer

Development Portfolio Focused on Near-Term Commercial Opportunities

HAYWARD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that Robert G. Johnson, Jr., M.D., Ph.D., has resigned as President and Chief Executive Officer and a member of Kosan's Board of Directors. Helen S. Kim, who joined Kosan in January 2008 as Senior Vice President and Chief Business Officer, has been appointed President of Kosan.

"Under Robert's leadership, Kosan made the successful transition from a research-oriented organization to a product development-focused company, and he has made many significant contributions to Kosan over the last eight years," said Peter Davis, Ph.D., Chairman of Kosan's Board of Directors. "Robert assumed the chief executive officer role during a period of transition and executed his responsibilities skillfully and energetically. He helped Kosan to manage a period of significant change to emerge as a better-positioned company and to recruit the senior management team that will help lead the company into its next phase. His commitment to Kosan has been intense, and his positive influence has been felt throughout the company. We express our sincerest thanks to Robert and wish him well in his new pursuits." Dr. Davis also noted: "Our new President, Helen Kim, has broad experience in product development and commercialization, as well as business and corporate development. These talents plus her demonstrated leadership will strengthen Kosan's ability to advance key product candidates toward the market."

Kosan also announced that the company has reprioritized its development portfolio. The compa
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
2. Kosan Announces February 28, 2008 Conference Call and Webcast
3. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
4. Kosan Announces Third Quarter 2007 Financial Results
5. Kosan to Reacquire Epothilone Program From Roche
6. Kosan Biosciences to Host Research & Development Day on October 31, 2007
7. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
8. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
9. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
10. Wyeth Announces Executive Change in Finance Organization
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Whitehouse Laboratories is excited to ... with PTI Inspection Systems that will enable ... the art leak testing method development and validation programs ... available. As part of this agreement, Whitehouse Labs has ... Detection Instrument developed and manufactured by PTI. The ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
(Date:8/27/2014)... Reportbuyer.com has added a new market ... A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds graphene, ... to water treatment, but is graphene the only ... Graphene Opportunity Report, authored by Tim Harper ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... YORK, Nov. 6 Morria Biopharmaceuticals,Plc, a biopharmaceutical ... data from its ICH compliant Phase II equivalent,multi-center ... allergic,rhinitis. MRX-4 was given as an intranasal spray ... was conducted in allergic,rhinitis patients outside of the ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a worldwide ... a conference call on Thursday, November 13,2008, at ... and operating,performance for its first fiscal quarter ended ... product development and marketing activities., Corgenix invites ...
... ... flavor enhancer may be used in beverages, foods and oral care ... to reduce the need for sucralose, SAN DIEGO, CA AND ... a leading company,focused on using proprietary technologies to discover and develop ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5
(Date:8/28/2014)... to Research Careers) Program has announced the travel award ... October 18 22, 2014 in San Diego, California. ... of students, post doctorates and scientists from underrepresented groups ... to encourage the participation of young scientists at the ... conferred 16 awards totaling $29,600., The FASEB MARC Program ...
(Date:8/28/2014)... Minn. A Mayo Clinic researcher and his collaborators ... up and enhance the process of re-engineering cells for ... uses network biology methods to aid stem cell engineering. ... engineering are described in two back-to-back papers in the ... a broad range of uses for all types of ...
(Date:8/28/2014)... Researchers at the University of Minnesota have developed an ... be used for muscle regeneration research as well as ... , The research is published in the current edition ... is no treatment for FSHD, which is thought by ... dystrophy. FSHD is an unusual genetic disorder because, unlike ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2UMN researchers find animal model for understudied type of muscular dystrophy 2
... Research Hospital have discovered that a certain differentiated cell ... it requires the constant expression of a gene called ... that Prox1 acts as a two-way switch whose inactivity ... called a lymphatic endothelial cell (LEC). In the absence ...
... and then presented with a chemoattractant signal like cAMP, individual ... a migrating stream. This is the first step in a ... organism. Kriebel et al. show how this streaming response is ... issue of the Journal of Cell Biology ( ...
... deformity known as pectus excavatum corrected report improved body ... published December in the journal Pediatrics . ... telephone interviews of more than 200 patients between the ... surgery. Researchers interviewed parents as well. The ...
Cached Biology News:Reprogrammable cell type depends on a single gene to keep its identity 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 2Marked improvement in body image, physical stamina, post-surgical pectus patients report 3
Request Info...
NATIVE RAT OSTEOCALCIN...
... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Biology Products: